IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

In honor of National CRNA Week (), U.S. House Representatives Jan Schakowsky (D-IL), Dave Joyce (R-OH), Suzanne Bonamici (D-OR), Brian Fitzpatrick (R-PA), Eleanor Holmes Norton (D-DC) and Paul Tonko ...

Environmental biotechnology is the branch of biotechnology that addresses environmental problems, such as the removal of pollution, renewable energy generation or biomass production, by exploiting ...

Since 2009, Adimab has partnered with over 130 pharmaceutical and biotechnology companies, generating more than 600 therapeutic programs, over 75 clinical programs, and multiple approved products. The ...

Backing from GV (Google Ventures), Iaso Ventures, and Virtue underscores ... commented: “Every day, biotech investors and business development professionals sift through huge amounts of data ...

In 2024, Fierce Biotech reported 192 industry layoff rounds, which is 3% higher than in 2023, when 187 rounds were tallied. Rounds are reported as they are disclosed and are not combined per ...

Re­gen­eron, mak­er of the block­buster oph­thal­mol­o­gy med­i­cine Eylea, has ac­quired an oc­u­lar biotech, the large bio­phar­ma con­firmed to End­points News on Thurs­day.

2024 was the year of the pri­vate megaround. Nine-fig­ure fi­nanc­ings dom­i­nat­ed biotech’s ven­ture fund­ing land­scape, with 96 such rounds tal­lied by End­points News. The bevy … ...

Carmell acquires Elevai Skincare, adding $2.5M in annual revenue and advanced exosome technology to its portfolio. Deal includes $1.1M in equity, $57K in cash, and earnouts tied to sales and ...

A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...